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Summary
Background: Management of extensive proximal femur bone loss secondary to tumor resec-
tion or major osteolysis remains controversial. The possible options include a composite
allograft/stem prosthesis, a modular type megaprosthesis or a custom-made megaprosthesis.
Modularity allows versatility at reconstruction and avoids the delay required manufacturing a
custom-made implant.
Hypothesis and type of study: A retrospective radiological and clinical study investigated
whether a special reconstruction modular stem design (JVC IXTM) would provide medium term
success in the treatment of severe proximal femur bone loss.
Material and methods: Between 1995 and 2005, 23 JVC IXTM hip replacements were performed
for severe segmental proximal femur bone loss. Etiology was: 13 cases of tumor resection, eight
of extensive osteolysis secondary to femoral implant loosening, and two traumatic situations.
Follow-up was annual. Functional assessment used the Musculo-Skeletal Tumor Score (MSTS),
and implant survival rates underwent Kaplan-Meier analysis, with surgical revision (to replace
or remove the implant) as the end point.
Results: All 23 patients (23 hips) were followed up for a mean 5.4 years (±3.7 yrs). Mean MSTS
was 16.2 (max. = 30). All stems demonstrated good ﬁxation at radiological assessment, except
for one case of probable loosening in contact with a metastatic osteolysis. Four implants had to
be revised: two for non-controlled infection, one for tumor extension, and one for stem fatigue
fracture. At 10 years’ follow-up, implant survivorship was 81.5% (range: 62% to 100%).
Discussion: Severe proximal femur bone loss is a difﬁcult situation to deal with, offering no
ideal treatment option. Modular megaprostheses are salvage procedures. Their results at a
mean 5.4 years’ follow-up are encouraging, and appear comparable to the ones obtained with
alternative solutions (composite allograft/stem prostheses).
Type of study: Level IV retrospective, therapeutic study.
© 2009 Elsevier Masson SAS. All rights reserved.
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ntroduction
anagement of extensive proximal segmental femoral bone
oss secondary to tumor resection or major osteolysis
emains controversial. Historically, the ﬁrst reconstructions
sed allograft. Failure rates were high, due to typical
llograft complications: infection, bone resorption, frac-
ure and graft non-union [1,2]. The alternative attitude is
rosthetic hip replacement, either by composite prosthesis
encased in an allograft) or by megaprosthesis [3,4]. The
mplant shows better mechanical resistance than with allo-
raft, but the technique runs a risk of secondary loosening
5]. To the best of our knowledge, neither technique (compo-
ite or megaprosthesis) has proved preferable in terms
f medium-term survivorship. Anract et al. [3] reported
7% 5-year survivorship in 20 composite prostheses and
3% for 20megaprostheses. Farid et al. [5] reported 86%
0-year survivorship in both 20 composite prostheses and
2megaprostheses.
Megaprostheses were at ﬁrst monoblocks, available in a
ange of sizes, then custom-made, and latterly modular. The
resent X-ray and clinical study reports results for modu-
ar reconstruction megaprostheses (JVC IXTM1) in a series of
3 cases of severe loss of proximal femoral substance at a
aximum 11 years’ follow-up.
aterial and methods
atients
his was a single-center multi-operator retrospective study
f the modular JVC IXTM megaprosthesis (Fig. 1). Between
anuary 1995 and January 2005, 23 hip replacements
23 patients) were performed, with none lost to follow-up.
t last follow-up, 10 patients (43%) had died, but could be
ncluded in the analysis on the basis of their last clinical and
-ray data.
Over the study period, the technique of interest was
ndicated for femoral reconstruction after proximal femoral
xtremity resection secondary to tumor or trauma, and for
emoral implant replacement due to endocortical osteolysis
xtending to the femoral stem (stage IV on Vives’ SOFCOT
lassiﬁcation [6].
The 23 patients had a mean age of 65± 17.2 years, with a
ender ratio of 0.3 (i.e., 5male, 18 female). Indications for
urgery comprised 13 tumor resections (56%), eight femoral
evisions for severe osteolysis (35%), and two cases of
rauma (9%). The 13 proximal femur tumors comprised four
igh-grade chondrosarcomas, four breast adenocarcinoma
etastases, two osteosarcomas (including 1 in a context of
brous dysplasia), one Ewing sarcoma, one plasmocytoma,
nd one epidermal amygdala cancer metastasis. The eight
emoral revisions comprised seven cases of recurrent (n > 2)
oosening and one Vancouver B3 periprosthetic fracture [7].
he two trauma cases were of complex trochanteric fracture
n elderly osteoporotic patients with history of neoplasia,
uggestive of pathological fracture.
1 JVC IXTM: Wright Medical Technology Inc., Arlington, Tennessee.
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sFigure 1 JVC IXTM modular megaprosthesis.
The patients were divided into two groups: group I, tumor
esection (n = 15); and group II, femoral revision (n = 8). The
wo trauma cases were included in group I, as their surgical
anagement followed the same design as for proximal femur
etastasis.
aterials
he JVC IXTM stem is a femoral stem with collar, of constant
ength, giving a 200mm anchorage in the distal femur. It is
ealed using methyl methacrylate.
A modular diaphyseal or metaphyseal component was ﬁt-
ed to the femoral stem. Apart from the 30mm metaphyseal
omponent, which has a ﬁxed neck, the other metaphy-
eal parts were adapted to a modular neck. The modular
etaphyseal-epiphyseal component, corresponding to the
esection level, had a mean height of 107± 45.2mm.
A bipolar arthroplasty was ﬁtted in nine cases (39%), and
n acetabular implant in 14 (61%): seven uncemented ﬁxed
ups, four cups sealed into a reinforcement ring, and three
ual mobility cups. Femoral head diameter was systemati-
ally 28mm.
urgical technique and postoperative course
ll implants were made after parenteral injection of antibi-
tics. The approach was systematically anterolateral, with
art of the greater trochanter ﬁxed to the prosthesis shoul-
er by steel wire in ten cases (45%), and gluteal reinsertion
n the other 13 (55%).Postoperatively, contact weight bearing was allowed with
imited active abduction for the ﬁrst three weeks, to enable
oft tissue healing.
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Table 1 Clinical results.
Group I: Tumor Group II: Femoral revision Total
MSTS 17.5 13.8 16.2
SD: 9.2 SD: 6.8 SD: 8.6
2.6 2.9
SD: 1.1 SD: 1.1
with initially satisfactory results gradually deteriorating due
to general deterioration in health status, and one complex
trochanteric fracture in an elderly patient who died due to
general complications three months postsurgery.
X-ray results
At last follow-up, there was one case of possible loosening
associated with metastatic osteolysis (breast adenocarci-
noma) at the distal third of the stem (group I), but no certain
loosening in the other 22 cases. Nineteen patients (82%)
showed stress-shielding osteolysis under cemented stem col-
lars during the ﬁrst year (Fig. 2); all these osteolysis were
asymptomatic and non-evolutive.
Complications
Nine patients experienced at least one complication (see
Table 2); the morbidity rate was 43.5% :
• four patients showed implant instability. Acetabular
revision was performed in three patients in group II
(2 antidislocation crescents and 1 dual mobility cup) and
orthopedic treatment for one patient in group I. No recur-
rence of instability was observed in these cases, althoughAbductor test 3
SD: 1.1
MSTS: musculo-skeletal tumor score [8].
Assessment
On follow-up, patients were assessed annually on Ennek-
ing et al.’s Musculo-Skeletal Tumor Society score (MSTS),
a lower-limb assessment adapted to tumor resection [8],
and in terms of abductor counter-resistance force in lateral
decubitus (max = 5). The MSTS provides a functional score on
six items, scored 0 to 5 each (i.e., max = 30): pain, walking
ability, gait handicap or limp, walking aids, overall function
and emotional acceptance. Results were considered excel-
lent for MSTS > 20, satisfactory for 10—20, and insufﬁcient
for MSTS < 10.
The X-ray analysis was carried out on the last images
with the original implant ﬁtted. We examined the presence
and spread of radiolucency on frontal and lateral views.
X-ray diagnoses of loosening were divided into three cat-
egories, following Harris et al. [9]: certain (obvious implant
migration), probable (circumferential radiolucency without
implant migration) and possible (radiolucency on at least
50% of the implant periphery).
Statistical analysis
Hips requiring revision and those in which the implant
remained in place were compared to explore reasons for
failure in terms of general examination ﬁndings, etiol-
ogy, extensive radiolucency, resection height, and greater
trochanteric vs. gluteal implant shoulder ﬁxation. Results
were also compared between groups I and II.
Comparison used 2 or Fisher’s exact tests for qualita-
tive variables according to application conditions, and the
Mann-Whitney non-parametric test for quantitative vari-
ables. Survivorship was plotted following Kaplan-Meier, with
a 95% conﬁdence interval. Revision for implant replacement
was considered as terminating implant survival.
Results
Clinical results
At a mean 5.4± 3.7 years’ FU, 19 implants (83%) were still
in place. Mean abductor force was 3± 1.1, and mean MSTS
16.2± 8.6 (see Table 1).
On MSTS, results were excellent in seven hips, satisfac-
tory in 10, and insufﬁcient in six. All seven excellent results
were in group I, and three had had greater trochanter or
trochanter medallion reinsertion. Three of the six patients
with insufﬁcient results died with the implant in place; there
were three implant infections after tumor resection, two
iterative revisions in elderly patients (mean age, 75 years)
Figure 2 Osteolysis under the collar of a cemented femoral
stem, with no clinical consequences.
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Table 2 Complications.
Type of complication Number of
cases
Group I
(rate)
Group II
(rate)
Treatment (n) Evolution
Implant instability 4 1
7%
3
37.5%
Antidislocation crescents
Dual mobility cup
Orthopedic
2
1
1
Simple
Simple
Simple
Deep infection 3 2
13%
1
12.5%
Medical
Femoral implant ablation
1
2
Death
1
disarticulation
and 1 cured
infection
Peri- or intraprosthetic
fracture
2 1
7%
1
12.5%
Implant replacement
Osteosynthesis
1
1
Simple
Consolidation
Tumor recurrence 2 2
13%
0
0%
Implant replacement
Osteosynthesis
1
1
Infection
Death
Stroke 1 1
7%
0
0%
Medical 1 Death
Table 3 Reoperation with femoral implant replacement.
Case Gender Age at
implantation
(years)
Group Post-op course
after the index
procedure
Failure etiology Failure interval
(years)
Procedure
1 F 78 II Cup replacement
for instability
Infection 5.1 1-step
removal/replacement
2 M 46 I Simple Fracture implant 2.6 Component
replacement
Infection 10.7 Disarticulation
Tumor recurrence 2.2 Total femur on TKR
•
•
•
•
•
R
F
5
i
• one deep infection occurred early after acetabular revi-
sion and was managed by 1-step implant removal and
replacement. At 4 years’ FU, there was no recurrence of
infection;
• one deep infection (group I) occurred late (at 4 years)
secondary to dental abscess and was treated by iter-
ative lavage and adapted antibiotherapy. Evolution
was adverse, with non-controlled and badly supported
infection. Disarticulation was performed 10.7 years post-
surgery;3 M 30 I Dental infection
4 F 68 I Tumor recurrence
TKR: total knee replacement.
one patient in group II contracted a deep infection requir-
ing implant replacement;
deep infection was found in three patients. One (group
I) was managed medically (antibiotherapy only) due to
severely degraded general health status and died 1 month
after initiation of treatment. The other two (group I and
group II) were managed by implant removal and replace-
ment;
one Vancouver C periprosthetic fracture (group II) was
consolidated by osteosynthesis;
one patient (group I) experienced femoral stem fracture,
requiring implant replacement;
tumor recurred in two cases (group I): one periprosthetic
fracture in a context of tumor recurrence in the distal
quarter of the femur, with possible stem loosening, was
managed by osteosynthesis; and the other fracture, man-
aged by femoral implant revision, failed to consolidate
and the patient died three years later;
ﬁnally, one patient (group I) suffered early postoperative
stroke and died within in the year.eoperation with femoral implant replacement
our implants (17%) were replaced during the mean
.4± 3.7 years’ follow-up. In two cases, this was due to
nfection, as noted above (see Table 3) (Fig. 3):
Figure 3 Example of a stem breakage. Neither mechanic nor
metallurgic failure were identiﬁed.
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gArthroplasty in severe femoral bone loss situations: Use of a
• one patient underwent revision for recurrence of tumor on
the remaining femur, due to non-respect of the resection
margins. Total femur implantation was performed on a
total knee replacement. A subsequent infection was man-
aged by iterative lavage and adapted antibiotherapy. At
2 years’ FU, a chronic ﬁstula required long-course antibio-
therapy;
• one patient (group I) experienced implant fracture
2.6 years postoperatively, at the junction between
diaphyseal and metaphyseal reconstruction compo-
nents. The implant was replaced, without further
complications.
Only one of these four cases (the implant fracture)
showed a satisfactory result for the revision, while the oth-
ers were considered insufﬁcient.
Statistical analysis
At 6 years’ FU, overall survivorship was 81.5% (62% to 100%).
No signiﬁcant impact on survivorship was found for any
revision risk factors in terms of general examination ﬁnd-
ings, etiology, resection height, trochanteric reinsertion or
complications.
Tumoral resection showed a non-signiﬁcant trend (p = 0.2)
towards giving better functional results than revision
for femoral loosening. There were no signiﬁcant differ-
ences in functional result according to abductor ﬁxation
technique.
Discussion
Surgical technique and material
In severe proximal femur bone-loss, surgical options are
between composite prostheses or megaprostheses (modu-
lar or custom-made). Using allograft around the implant
has the theoretical advantage of reconstituting bone cap-
ital, improving femoral anchorage (thereby reducing the
incidence of femoral loosening), and achieving biologi-
cal reinsertion of the abductor apparatus — which should
in principle provide a better functional result [3,5].
The advantages of megaprostheses lie in their ready
availability and easier implantation technique, and the
avoidance of using human-derivative material. Megapros-
theses were initially monoblocks; although these came in
a range of sizes, adaptation to the exact bone-loss was
suboptimal. Custom-made megaprostheses were then devel-
oped, but involved a manufacturing delay. More recently,
modular megaprostheses appeared, providing a certain
ﬂexibility in resection (adjustment, freedom of choice,
adaptability) thanks to peroperative modular assembly
[2].
The choice of megaprostheses for complex
pertrochanteric fractures is debatable, but here the
aspect resembled metastatic fracture, and they were man-
aged as such even though subsequent anatomopathological
analysis proved negative. We agree with Wedin and Bauer
[10] that implanting is less risky than osteosynthesis for
proximal femur metastatic locations.
t
D
I
aigure 4 In this tumor case, partial conservation of the great
rochanter enabled an excellent clinical and functional result.
unctional results
his was a heterogeneous series, and the results are hard
o compare. There was a trend towards better functional
esults in the tumor resection group as compared to the
emoral revision group, the former comprising younger
atients without history of surgery.
In the tumor resection group, results were satisfactory
mean MSTS, 17.5), but still lower than those of Menen-
ez et al. [11], who reported a mean MSTS score of 22 at
mean 18months’ FU for 96modular megaprostheses, with
he same etiology but excluding revision cases. The present
esults in the femoral revision group were poor, with a mean
STS score of 13.8. Even so, we consider a large modular
emoral stem as a salvage solution in case of iterative revi-
ion. Parvizi et al. [12] recommend using this type of implant
n this indication only in elderly patients with a low level of
unctional demand.
Functionally, the various abductor muscle reinsertion
echniques did not provide signiﬁcantly different results.
owever, the three excellent results obtained with reinser-
ion of the greater trochanter or a trochanteric medallion
Fig. 4) lead us to consider this as an important point in
mproving MSTS score and abduction force. Indeed, the
ontinuity of the abductor apparatus ensured by biologi-
al ﬁxation of the muscles onto an allograft can account
or the trend towards better functional results found with
ompound prostheses compared to megaprostheses [3,5].
ven so, neither Anract et al. [3] nor Farid et al. [5] reported
igniﬁcant differences between these two reconstruction
roups, and one technique cannot be asserted to be better
han the other from a functional point of view.islocation
n the femoral revision group, the dislocation rate was 37.5%
nd instability was the main reason for revision, and is
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[96
ndeed the most frequent complication following megapros-
hetic reconstruction in non-tumoral etiologies [12], with
islocation rates ranging from 16% to 22% depending on the
eries [13,14]. To limit this risk, Parvizi et al. [12] recom-
end using a retention cup and postoperative bracing to
mmobilize the hip in abduction in case of iterative femoral
evision. In our opinion, dual mobility cups could limit this
omplication, although to the best of our knowledge there
ave been no studies assessing this implant association in
terative revision.
In the tumor resection group, there was one episode of
islocation (dislocation rate = 7%). These results are compa-
able to those of Kabukcuoglu et al. [15], who reported
n 11% dislocation rate in 54megaprostheses for primi-
ive tumor, with ﬁxed-cup acetabular reconstruction. Tumor
esection seems to involve a greater risk of instability than
oes iterative revision. Even so, we recommend using a
arge head (bipolar or intermediate reinforcement cup or
ual mobility cup). Bipolar prostheses may be reserved to
atients with short life expectancy, with dual mobility cups
ndicated in other cases. In young active patients, there is
n issue of friction couple wear; the risk of implant instabil-
ty then has to be set against that of accelerated wear with
dual mobility cup.
nfection
he overall infection rate in the present series was very high
12.5%) and comparable in groups I and II. In femoral revi-
ion, Haentjens et al. [13] had a similar infection rate of
6%. In tumor resection, infection rates vary from 3% to 13%
ccording to the series [16,17,18], well below the 30% rate
eported with allograft reconstruction [19]. There is little
n the way of speciﬁc action to reduce this risk. Very con-
roversially, Malawer and Chou [17] recommend systematic
robabilistic antibiotherapy during postoperative immuno-
uppression in femoral revision.
mplant survivorship
t 10 years’ follow-up overall survivorship was 81.5%, and
00% at 2 years. These results are comparable to those of
arid et al. [5], who reported identical 86% 10-year sur-
ivorship for both types of implant (20 composite prostheses
nd 32megaprostheses). Menedez et al. [11] reported 82%
0-year survivorship for 96modular megaprostheses.
In the present series, there were no cases of aseptic
oosening. This may be due to advances in cementing tech-
iques, or to implant design. If, however, the implants
ystematically survived longer than their bearers, it is to
e borne in mind that this was probably due to the high rate
f mortality in the ﬁrst 3 years following implantation.
The rate of loosening may therefore rise over longer
ollow-up, especially as some implants were in young and
ctive patients. In some studies the failure rate associated
ith loosening was 10% to 16% [16,20]; but they, like the
resent study, were biased by the heterogeneity of their
ecruitment, precluding satisfactory assessment of failure
ue to mechanical causes. In the present series, there was
ne case of implant fracture, with no mechanical or metal-
urgic explanation.
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onclusions
evere proximal femoral bone-loss creates a difﬁcult sit-
ation with no ideal treatment option. While the distal
nchorage is the real weak point in reconstruction pros-
heses, the present study uncovered no sure loosening of
he femoral stem at a mean 5.4 years’ follow-up. Mod-
larity optimized adaptation to the precise bone-loss,
hatever the context (tumor or revision surgery). Modular
egaprostheses represent a salvage solution, with encour-
ging medium-term results. They seem ideally indicated for
xtensive proximal femoral bone-loss in patients with lim-
ted life expectancy.
onﬂict of interest
one.
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